You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 25, 2025

Drug Price Trends for ARTHRITIS PAIN ER


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for ARTHRITIS PAIN ER

Average Pharmacy Cost for ARTHRITIS PAIN ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
ARTHRITIS PAIN ER 650 MG TAB 50268-0052-11 0.06875 EACH 2025-04-23
ARTHRITIS PAIN ER 650 MG CAPLT 51660-0333-50 0.06875 EACH 2025-04-23
ARTHRITIS PAIN ER 650 MG TAB 50268-0052-15 0.06875 EACH 2025-04-23
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Arthritis Pain ER

Introduction to Arthritis Pain ER

Arthritis Pain ER, often formulated with acetaminophen or other analgesics, is a crucial component of the pain management drugs market. These extended-release formulations are designed to provide prolonged pain relief, making them a preferred option for managing chronic pain conditions such as arthritis.

Market Size and Growth Projections

The global pain management drugs market, which includes arthritis pain medications, is projected to reach $109.6 billion by 2033, growing at a CAGR of 4.2% from 2024 to 2033[1].

Segment Analysis: Arthritis Pain

Within the pain management market, the arthritic pain segment is expected to capture a significant market share during the forecast period. This is driven by the increasing prevalence of chronic pain conditions such as arthritis and back pain[3].

Drug Class and Formulations

Arthritis Pain ER typically falls under the category of analgesics, which include NSAIDs, opioids, and non-opioid alternatives like acetaminophen. Extended-release formulations, such as those found in Tylenol Arthritis Pain, are particularly popular due to their ability to provide sustained pain relief with reduced dosing frequency[1][2].

Price Analysis

The cost of Arthritis Pain ER medications can vary based on the formulation, brand, and pharmacy. For example, Tylenol Arthritis Pain 650 mg oral tablet, extended release, can cost around $7.69 for a supply of 24 tablets, depending on the pharmacy and any discounts applied[2].

Quantity Per Unit Price
24 $0.32 $7.69
50 $0.20 $10.19
100 $0.14 $13.94
150 $0.11 $16.53
290 $0.07 $19.45

Market Drivers

Several factors drive the growth of the arthritis pain management market:

  • Increasing Prevalence of Chronic Pain Conditions: The rise in chronic diseases such as arthritis, heart disease, and diabetes contributes significantly to the demand for pain management drugs[1].
  • Advancements in Pharmaceutical Research: Novel drug formulations and delivery methods, such as extended-release and non-opioid alternatives, enhance efficacy, safety, and patient compliance[1].
  • Growing Geriatric Population: The increasing age of the population makes them more prone to pain-related disorders, further driving the market[1].

Recent Developments and Innovations

The pain management drugs market is witnessing significant innovations:

  • Non-Opioid Alternatives: Companies like Allay Therapeutics are developing ultra-sustained analgesic products that provide non-opioid pain relief lasting up to two weeks after a single administration[1].
  • Selective Inhibitors: Vertex Pharmaceuticals has announced positive results for its selective NaV1.8 inhibitor, VX-548, which is being developed for the treatment of moderate-to-severe acute pain[1].

Distribution Channels

The hospital pharmacy segment holds the largest share of the pain management drugs market and is expected to sustain this position throughout the forecast period. This indicates that a significant portion of arthritis pain medications are prescribed and dispensed through hospital settings[3].

Competitive Landscape

Key market players in the pain management drugs market include Eli Lilly & Company, GlaxoSmithKline Plc, Pfizer, Inc., Novartis AG, and Johnson & Johnson. These companies are continuously investing in research and development to introduce innovative pain management solutions[1].

Regulatory Environment

The FDA has been active in addressing substance use and overdose prevention, particularly with opioids. For instance, the FDA approved Targiniq ER, an extended-release pain reliever with abuse-deterrent properties, and revised the ER/LA Opioid Analgesics REMS to clarify indications and warnings[5].

Consumer Preferences and Awareness

There is a growing preference for non-opioid alternatives and multimodal approaches to pain management. This shift is driven by concerns about the addictive potential and adverse effects of traditional opioid medications. As awareness and acceptance of these alternatives increase, the market for arthritis pain ER medications is likely to expand[1].

Key Takeaways

  • The global pain management drugs market, including arthritis pain ER, is projected to reach $109.6 billion by 2033.
  • The arthritic pain segment is expected to capture a significant market share.
  • Extended-release formulations like Tylenol Arthritis Pain are popular due to their sustained pain relief.
  • Non-opioid alternatives and innovative drug formulations are driving market growth.
  • Hospital pharmacies dominate the distribution channels for these medications.

Frequently Asked Questions (FAQs)

Q1: What is the projected market size for pain management drugs by 2033? The global pain management drugs market is projected to reach $109.6 billion by 2033[1].

Q2: Which segment is expected to dominate the pain management market? The opioids segment is expected to dominate the market, although non-opioid alternatives are gaining traction[1][3].

Q3: What are the key drivers of the arthritis pain management market? Key drivers include the increasing prevalence of chronic pain conditions, advancements in pharmaceutical research, and a growing geriatric population[1].

Q4: How much does Tylenol Arthritis Pain ER typically cost? Tylenol Arthritis Pain 650 mg oral tablet, extended release, can cost around $7.69 for a supply of 24 tablets[2].

Q5: What recent innovations are seen in the pain management market? Recent innovations include the development of non-opioid alternatives and selective inhibitors like VX-548 by Vertex Pharmaceuticals[1].

Sources:

  1. Allied Market Research - Pain Management Drugs Market Size, Share | Forecast - 2033
  2. Drugs.com - Tylenol Arthritis Pain Prices, Coupons, Copay Cards & Patient Assistance
  3. BioSpace - U.S. Pain Management Drugs Market Size and Growth, Statistics 2024 to 2033
  4. Verified Market Research - Tofacitinib Market Size & Forecast
  5. FDA - Overdose Prevention Activities Timeline - FDA

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.